News Detail

Cabaletta Bio prices 51,725,000-share offering at $2.9, raises $150 million

PUBT · 16h ago

Listen to the news

Cabaletta Bio prices 51,725,000-share offering at $2.9, raises $150 million

Cabaletta Bio priced an underwritten follow-on offering of 51,725,000 common shares, targeting gross proceeds of about USD 150 million.
Offering priced at USD 2.9 per share, described as at-the-market under Nasdaq rules.
Closing expected on or about May 5, 2026, subject to customary conditions.
Bain Capital Life Sciences, Adage Capital Management, Cormorant Asset Management, other existing investors, new mutual and sovereign wealth funds, Eli Lilly participated.
TD Cowen, Guggenheim Securities, Cantor serving as joint bookrunners; H.C. Wainwright acting as lead manager.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cabaletta Bio Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605040635PRIMZONEFULLFEED9712227) on May 04, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.

What's Trending

No content on the Webull website shall be considered a recommendation or solicitation for the purchase or sale of securities, options or other investment products. All information and data on the website is for reference only and no historical data shall be considered as the basis for judging future trends.